TOLMAR, INC.
FORT COLLINS, CO

Tolmar, Inc., a privately held specialty pharmaceutical company, is recognized for its strategic focus on science-driven innovation to enhance patient care through advanced therapies and services. With a commitment to excellence and technological advancement, Tolmar serves urology, oncology, and dermatology markets, exemplified by the globally approved ELIGARD® (leuprolide acetate for injectable suspension). The company excels with an integrated model overseeing all research, development, approval, and commercialization processes. Notably headquartered in Northern Colorado with facilities across the U.S., Tolmar operates under robust regulatory standards supported by a global reputation for manufacturing excellence and clinical development. Founded in 2006, Tolmar employs over 700 team members who collectively pursue progress through partnerships, product innovation, and patient-focused initiatives. With more than 21 marketed products bolstered by extensive New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs), Tolmar's pipeline underscores an ongoing commitment to healthcare advancements. The company’s culture is grounded in values that prioritize ethical compliance, corporate responsibility, and a mission-centric approach toward improving global patient outcomes. With a significant presence in the U.S., including key commercial operations directed by experienced leaders such as CEO Anil D'Souza and Director Jeff Lederman, Tolmar continues to expand its role with investments in cutting-edge technologies. For more insights, Tolmar's official website can be accessed at tolmar.com.